KR101969601B1 - 옥심 결합용 친핵성 촉매 - Google Patents

옥심 결합용 친핵성 촉매 Download PDF

Info

Publication number
KR101969601B1
KR101969601B1 KR1020137004971A KR20137004971A KR101969601B1 KR 101969601 B1 KR101969601 B1 KR 101969601B1 KR 1020137004971 A KR1020137004971 A KR 1020137004971A KR 20137004971 A KR20137004971 A KR 20137004971A KR 101969601 B1 KR101969601 B1 KR 101969601B1
Authority
KR
South Korea
Prior art keywords
therapeutic protein
soluble polymer
group
protein
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137004971A
Other languages
English (en)
Korean (ko)
Other versions
KR20130043211A (ko
Inventor
위르겐 지크만
스테판 하이더
한스페터 로텐스타이너
안드레아스 이벤스
페터 투레첵
올리버 죄흘링
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20130043211A publication Critical patent/KR20130043211A/ko
Application granted granted Critical
Publication of KR101969601B1 publication Critical patent/KR101969601B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020137004971A 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매 Active KR101969601B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36918610P 2010-07-30 2010-07-30
US61/369,186 2010-07-30
PCT/US2011/045873 WO2012016131A1 (en) 2010-07-30 2011-07-29 Nucleophilic catalysts for oxime linkage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010071A Division KR102088852B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매

Publications (2)

Publication Number Publication Date
KR20130043211A KR20130043211A (ko) 2013-04-29
KR101969601B1 true KR101969601B1 (ko) 2019-04-17

Family

ID=44629987

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020137004971A Active KR101969601B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020207006813A Active KR102172133B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020217018874A Active KR102325780B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020217007514A Active KR102269494B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020207030594A Active KR102229967B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020197010071A Active KR102088852B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020207006813A Active KR102172133B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020217018874A Active KR102325780B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020217007514A Active KR102269494B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020207030594A Active KR102229967B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매
KR1020197010071A Active KR102088852B1 (ko) 2010-07-30 2011-07-29 옥심 결합용 친핵성 촉매

Country Status (26)

Country Link
EP (3) EP2598172B1 (enExample)
JP (7) JP6325818B2 (enExample)
KR (6) KR101969601B1 (enExample)
CN (3) CN108079312A (enExample)
AR (1) AR082941A1 (enExample)
AU (1) AU2011282571C1 (enExample)
BR (1) BR112013001611B1 (enExample)
CA (1) CA2806684C (enExample)
CY (1) CY1121943T1 (enExample)
DK (1) DK2598172T3 (enExample)
EA (2) EA201691292A1 (enExample)
ES (1) ES2731626T3 (enExample)
HR (1) HRP20190990T1 (enExample)
HU (1) HUE043790T2 (enExample)
LT (1) LT2598172T (enExample)
MX (1) MX346271B (enExample)
NZ (1) NZ605972A (enExample)
PL (1) PL2598172T3 (enExample)
PT (1) PT2598172T (enExample)
RS (1) RS58900B1 (enExample)
SG (2) SG187171A1 (enExample)
SI (1) SI2598172T1 (enExample)
SM (1) SMT201900351T1 (enExample)
TR (1) TR201908836T4 (enExample)
TW (1) TWI534152B (enExample)
WO (1) WO2012016131A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
EP2654794B8 (en) 2010-12-22 2020-04-22 Baxalta GmbH Materials and methods for conjugating a water soluble fatty acid derivative to a protein
GB2516388A (en) * 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
MX2018004296A (es) 2015-10-08 2018-08-01 Nektar Therapeutics Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
US20170349644A1 (en) * 2015-12-03 2017-12-07 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties
EP3487538A1 (en) 2016-07-22 2019-05-29 Nektar Therapeutics Conjugates of a factor viii moiety having an oxime-containing linkage
WO2018213341A1 (en) 2017-05-15 2018-11-22 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
SG11202107497XA (en) 2019-01-23 2021-08-30 Regeneron Pharma Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
EP4298219A1 (en) 2021-02-26 2024-01-03 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
WO2025133203A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
WO2008025856A2 (en) * 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
NZ256921A (en) 1992-10-02 1996-05-28 Pharmacia Ab Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5574187A (en) * 1994-10-06 1996-11-12 Uniroyal Chemical Company, Inc. Process of preparing para substituted phenylamines
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
ES2256234T3 (es) 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
CA2496317C (en) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
ES2512499T3 (es) 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Fármacos pegilados reversibles
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
TWI356065B (en) * 2003-08-08 2012-01-11 Fresenius Kabi De Gmbh Method of producing hydroxyalkyl starch derivative
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ547554A (en) 2003-12-03 2009-09-25 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
ES2593318T3 (es) 2004-08-12 2016-12-07 Lipoxen Technologies Limited Derivados de ácido siálico
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
CN101242858B (zh) 2005-06-16 2012-12-19 尼克塔治疗公司 具有可降解键的轭合物以及用于制备这种轭合物的聚合物试剂
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CN101535339B (zh) * 2006-09-01 2014-11-12 诺沃-诺迪斯克保健股份有限公司 改性糖蛋白
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
EP2201953A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
EP3081233B1 (en) * 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
AU2010281453C1 (en) * 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
KR20120060209A (ko) * 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ｉｘ 폴리펩티드 및 그의 용도
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
WO2008025856A2 (en) * 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins

Also Published As

Publication number Publication date
RS58900B1 (sr) 2019-08-30
KR20210032542A (ko) 2021-03-24
KR20200126008A (ko) 2020-11-05
EA201300190A1 (ru) 2013-07-30
EP2598172B1 (en) 2019-03-27
EA025738B9 (ru) 2018-05-31
EP3505186B1 (en) 2022-01-12
BR112013001611A8 (pt) 2020-10-27
EA025738B1 (ru) 2017-01-30
JP2019116501A (ja) 2019-07-18
TR201908836T4 (tr) 2019-07-22
CN108079312A (zh) 2018-05-29
KR20130043211A (ko) 2013-04-29
KR102325780B1 (ko) 2021-11-12
TW201217393A (en) 2012-05-01
KR102269494B1 (ko) 2021-06-25
SI2598172T1 (sl) 2019-08-30
JP2022046676A (ja) 2022-03-23
KR102229967B1 (ko) 2021-03-19
HUE043790T2 (hu) 2019-09-30
BR112013001611A2 (pt) 2016-05-17
AU2011282571C1 (en) 2018-04-05
BR112013001611B1 (pt) 2022-05-10
EP3505186A1 (en) 2019-07-03
PL2598172T3 (pl) 2019-09-30
MX346271B (es) 2016-07-08
KR20190040364A (ko) 2019-04-17
JP7054407B2 (ja) 2022-04-13
KR20210079392A (ko) 2021-06-29
CY1121943T1 (el) 2020-10-14
KR102172133B1 (ko) 2020-11-02
JP2021038256A (ja) 2021-03-11
CN108079311A (zh) 2018-05-29
JP2019116500A (ja) 2019-07-18
PT2598172T (pt) 2019-06-25
JP2013536180A (ja) 2013-09-19
CA2806684A1 (en) 2012-02-02
SG187171A1 (en) 2013-02-28
CA2806684C (en) 2020-11-17
WO2012016131A1 (en) 2012-02-02
JP2015164958A (ja) 2015-09-17
AU2011282571B2 (en) 2015-09-24
ES2731626T3 (es) 2019-11-18
KR20200029059A (ko) 2020-03-17
NZ605972A (en) 2015-04-24
EA201691292A1 (ru) 2017-08-31
CN103370082A (zh) 2013-10-23
HRP20190990T1 (hr) 2019-10-04
AU2011282571A1 (en) 2013-02-07
EP2598172A1 (en) 2013-06-05
LT2598172T (lt) 2019-08-26
DK2598172T3 (da) 2019-07-01
MX2013001261A (es) 2013-03-22
JP2017137358A (ja) 2017-08-10
TWI534152B (zh) 2016-05-21
AR082941A1 (es) 2013-01-23
EP4023247A1 (en) 2022-07-06
JP6757823B2 (ja) 2020-09-23
SG10201913078SA (en) 2020-02-27
JP7258999B2 (ja) 2023-04-17
SMT201900351T1 (it) 2019-07-11
JP6325818B2 (ja) 2018-05-16
KR102088852B1 (ko) 2020-03-16

Similar Documents

Publication Publication Date Title
JP7258999B2 (ja) オキシム連結のための求核触媒
JP7304402B2 (ja) オキシム連結のための求核触媒

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20160422

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160725

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180601

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190208

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180601

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190208

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181001

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160725

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190322

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190313

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190208

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20181001

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160725

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190408

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190410

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190410

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220324

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230323

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240401

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250324

Start annual number: 7

End annual number: 7